Johnson & Johnson (NYSE: JNJ) announced Friday that its single-dose coronavirus vaccine was currently 66% effective against Covid-19. Nevertheless, the vaccine seems to be less efficient when it comes to other variants of the virus.
The company’s one-shot dose has several advantages over the two already on the market. J&J’s vaccine does not require ultra-cold storage or the need for a second shot.
“I think it’s going to be very useful in states that have large rural populations because storage requirements are less demanding,” said Dr. Jon Klein, vice-dean for research at U of L. “I think it’s going to be very useful for people who have transportation problems, and there are many who simply do not have access to a car.”
According to the Food and Drug Administration it will authorize vaccines that are at a minimum 50% effective. Johnson & Johnson is set to seek emergency use authorization by February, if granted it it will join both Pfizer and Moderna.
The vaccine was 72% effective within the United States, 66% in Latin America and 57% in South Africa, offering an overall protection of 66% after four weeks. J&J revealed that the vaccine was also 85% efficient in impeding severe disease four weeks after taking the shot within all adults.
“We’re proud to have reached this critical milestone and our commitment to address this global health crisis continues with urgency for everyone, everywhere,” J&J CEO Alex Gorsky said in a statement.
The nation’s leading infectious disease expert, Dr. Anthony Fauci, stated that the most important results from the vaccine data was that it could keep people out of hospitals or from contracting severe illness.
“The most important thing, more important than whether you prevent someone from getting aches and a sore throat, is preventing people” from getting severe disease, the director of the National Institute of Allergy and Infectious Diseases said on a call with reporters. “That will alleviate so much of the stress and human suffering and death in this epidemic.”